FFO
EWTX icon

Fortitude Family Office’s Edgewise Therapeutics EWTX Stock Holding History

Fortitude Family Office’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.5K Hold
160
– – ﹤0.01% 960
2026
Q1 		$5.04K Hold
160
– – ﹤0.01% 906
2025
Q4 		$3.97K Hold
160
– – ﹤0.01% 903
2025
Q3 		$2.6K Hold
160
– – ﹤0.01% 1105
2025
Q2 		$2.1K Hold
160
– – ﹤0.01% 1175
2025
Q1 		$3.52K Hold
160
– – ﹤0.01% 817
2024
Q4 		$4.27K Hold
160
– – ﹤0.01% 889
2024
Q3 		$4.27K Hold
160
– – ﹤0.01% 832
2024
Q2 		$2.88K Hold
160
– – ﹤0.01% 737
2024
Q1 		$2.92K Hold
160
– – ﹤0.01% 754
2023
Q4 		$1.75K Buy
+160
New +$1.12K ﹤0.01% 890

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fortitude Family Office's EWTX Position: Q2 2026 in Review

Fortitude Family Office held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 160 shares worth $6.5K. The position accounts for ﹤0.01% of the portfolio, ranked #960.

Fortitude Family Office first reported a position in EWTX in Q4 2023 and has held it in 11 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Fortitude Family Office held 160 shares of Edgewise Therapeutics worth $6.5K as of Q2 2026.
  • Fortitude Family Office left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #960 holding.
  • Fortitude Family Office first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.